Who needs venture backers? Bill Haney bags new deal cash from Celgene as his biotech upstart Dragonfly explores NK cell tech
Bill Haney continues to build Dragonfly Therapeutics one deal at a time. And now he’s banking more cash as he grows the company into an I/O player to reckon with.
Celgene is handing over $24 million to bag the worldwide licensing rights on a pair of hematology therapies, paying $12 million apiece just weeks after the big biotech agreed to double down on their alliance with the Cambridge, MA-based startup and expand the work with 4 new targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.